399 related articles for article (PubMed ID: 29246230)
41. Regulator of Calcineurin 1 Gene Isoform 4, Down-regulated in Hepatocellular Carcinoma, Prevents Proliferation, Migration, and Invasive Activity of Cancer Cells and Metastasis of Orthotopic Tumors by Inhibiting Nuclear Translocation of NFAT1.
Jin H; Wang C; Jin G; Ruan H; Gu D; Wei L; Wang H; Wang N; Arunachalam E; Zhang Y; Deng X; Yang C; Xiong Y; Feng H; Yao M; Fang J; Gu J; Cong W; Qin W
Gastroenterology; 2017 Sep; 153(3):799-811.e33. PubMed ID: 28583823
[TBL] [Abstract][Full Text] [Related]
42. Role of AMP-activated protein kinase activators in antiproliferative multi-drug pituitary tumour therapies: effects of combined treatments with compounds affecting the mTOR-p70S6 kinase axis in cultured pituitary tumour cells.
Tulipano G; Faggi L; Cacciamali A; Spinello M; Cocchi D; Giustina A
J Neuroendocrinol; 2015 Jan; 27(1):20-32. PubMed ID: 25323047
[TBL] [Abstract][Full Text] [Related]
43. TRIM29 modulates proteins involved in PTEN/AKT/mTOR and JAK2/STAT3 signaling pathway and suppresses the progression of hepatocellular carcinoma.
Yin YT; Shi L; Wu C; Zhang MY; Li JX; Zhou YF; Wang SC; Wang HY; Mai SJ
Med Oncol; 2024 Feb; 41(3):79. PubMed ID: 38393440
[TBL] [Abstract][Full Text] [Related]
44. Down-Regulated NRSN2 Promotes Cell Proliferation and Survival Through PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma.
Wang X; Han L; Zhang J; Xia Q
Dig Dis Sci; 2015 Oct; 60(10):3011-8. PubMed ID: 26055238
[TBL] [Abstract][Full Text] [Related]
45. MiR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway.
Lou G; Chen L; Xia C; Wang W; Qi J; Li A; Zhao L; Chen Z; Zheng M; Liu Y
J Exp Clin Cancer Res; 2020 Jan; 39(1):4. PubMed ID: 31898515
[TBL] [Abstract][Full Text] [Related]
46. Modulation of the de novo purine nucleotide pathway as a therapeutic strategy in mitochondrial myopathy.
Kimoloi S
Pharmacol Res; 2018 Dec; 138():37-42. PubMed ID: 30267763
[TBL] [Abstract][Full Text] [Related]
47. The activation of MEK/ERK signaling pathway by bone morphogenetic protein 4 to increase hepatocellular carcinoma cell proliferation and migration.
Chiu CY; Kuo KK; Kuo TL; Lee KT; Cheng KH
Mol Cancer Res; 2012 Mar; 10(3):415-27. PubMed ID: 22241220
[TBL] [Abstract][Full Text] [Related]
48. The kinetic mechanism of the human bifunctional enzyme ATIC (5-amino-4-imidazolecarboxamide ribonucleotide transformylase/inosine 5'-monophosphate cyclohydrolase). A surprising lack of substrate channeling.
Bulock KG; Beardsley GP; Anderson KS
J Biol Chem; 2002 Jun; 277(25):22168-74. PubMed ID: 11948179
[TBL] [Abstract][Full Text] [Related]
49. Aspirin induces Beclin-1-dependent autophagy of human hepatocellular carcinoma cell.
Huang Z; Fang W; Liu W; Wang L; Liu B; Liu S; Liu S
Eur J Pharmacol; 2018 Mar; 823():58-64. PubMed ID: 29408091
[TBL] [Abstract][Full Text] [Related]
50. Rapamycin regulates the proliferation of Huh7, a hepatocellular carcinoma cell line, by up-regulating p53 expression.
Kwon S; Jeon JS; Ahn C; Sung JS; Choi I
Biochem Biophys Res Commun; 2016 Oct; 479(1):74-9. PubMed ID: 27616194
[TBL] [Abstract][Full Text] [Related]
51. ATIC-Associated De Novo Purine Synthesis Is Critically Involved in Proliferative Arterial Disease.
Ma Q; Yang Q; Xu J; Zhang X; Kim D; Liu Z; Da Q; Mao X; Zhou Y; Cai Y; Pareek V; Kim HW; Wu G; Dong Z; Song WL; Gan L; Zhang C; Hong M; Benkovic SJ; Weintraub NL; Fulton D; Asara JM; Ben-Sahra I; Huo Y
Circulation; 2022 Nov; 146(19):1444-1460. PubMed ID: 36073366
[TBL] [Abstract][Full Text] [Related]
52. UBE2O promotes hepatocellular carcinoma cell proliferation and invasion by regulating the AMPKα2/mTOR pathway.
Shi Z; Liu R; Lu Q; Zeng Z; Liu Y; Zhao J; Liu X; Li L; Huang H; Yao Y; Huang D; Xu Q
Int J Med Sci; 2021; 18(16):3749-3758. PubMed ID: 34790050
[TBL] [Abstract][Full Text] [Related]
53. SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway.
Zhou C; Liu C; Liu W; Chen W; Yin Y; Li CW; Hsu JL; Sun J; Zhou Q; Li H; Hu B; Fu P; Atyah M; Ma Q; Xu Y; Dong Q; Hung MC; Ren N
Theranostics; 2020; 10(10):4627-4643. PubMed ID: 32292519
[TBL] [Abstract][Full Text] [Related]
54. Antroquinonol displays anticancer potential against human hepatocellular carcinoma cells: a crucial role of AMPK and mTOR pathways.
Chiang PC; Lin SC; Pan SL; Kuo CH; Tsai IL; Kuo MT; Wen WC; Chen P; Guh JH
Biochem Pharmacol; 2010 Jan; 79(2):162-71. PubMed ID: 19723512
[TBL] [Abstract][Full Text] [Related]
55. AICA-ribosiduria: a novel, neurologically devastating inborn error of purine biosynthesis caused by mutation of ATIC.
Marie S; Heron B; Bitoun P; Timmerman T; Van Den Berghe G; Vincent MF
Am J Hum Genet; 2004 Jun; 74(6):1276-81. PubMed ID: 15114530
[TBL] [Abstract][Full Text] [Related]
56. E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer.
Ladu S; Calvisi DF; Conner EA; Farina M; Factor VM; Thorgeirsson SS
Gastroenterology; 2008 Oct; 135(4):1322-32. PubMed ID: 18722373
[TBL] [Abstract][Full Text] [Related]
57. Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells.
Baumann P; Mandl-Weber S; Emmerich B; Straka C; Schmidmaier R
Exp Cell Res; 2007 Oct; 313(16):3592-603. PubMed ID: 17669398
[TBL] [Abstract][Full Text] [Related]
58. Characterization of two 5-aminoimidazole-4-carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase isozymes from Saccharomyces cerevisiae.
Tibbetts AS; Appling DR
J Biol Chem; 2000 Jul; 275(27):20920-7. PubMed ID: 10877846
[TBL] [Abstract][Full Text] [Related]
59. Case report of a rare purine synthesis disorder due to 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (AICAR) deficiency.
Joy P; Madhuri V; Palocaren T; Das S; Susan Cleave Abraham S; Korula S; Koshy B; Jose J; Chandran M; Danda S
Brain Dev; 2022 Oct; 44(9):645-649. PubMed ID: 35637059
[TBL] [Abstract][Full Text] [Related]
60. Liver fatty acid-binding protein (L-FABP) promotes cellular angiogenesis and migration in hepatocellular carcinoma.
Ku CY; Liu YH; Lin HY; Lu SC; Lin JY
Oncotarget; 2016 Apr; 7(14):18229-46. PubMed ID: 26919097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
